Spinal Muscular Atrophy Stocks List

Recent Signals

Date Stock Signal Type
2021-05-14 ALNY 20 DMA Resistance Bearish
2021-05-14 BIIB Upper Bollinger Band Walk Strength
2021-05-14 IONS NR7 Range Contraction
2021-05-14 IONS 1,2,3 Retracement Bearish Bearish Swing Setup
2021-05-14 IONS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 PRAX Pocket Pivot Bullish Swing Setup
2021-05-14 PRAX Volume Surge Other
2021-05-14 PRAX Stochastic Buy Signal Bullish
2021-05-14 PRAX Lower Bollinger Band Walk Weakness
2021-05-14 PRAX Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-14 PTCT New 52 Week Closing Low Bearish
2021-05-14 PTCT New 52 Week Low Weakness
2021-05-14 PTCT NR7 Range Contraction
2021-05-14 PTCT Hammer Candlestick Bullish
2021-05-14 PTCT Lizard Bullish Bullish Day Trade Setup
2021-05-14 TVTX Hammer Candlestick Bullish
2021-05-14 TVTX Lower Bollinger Band Walk Weakness
2021-05-14 TVTX Calm After Storm Range Contraction
2021-05-14 TVTX Volume Surge Other

Recent News for Spinal Muscular Atrophy Stocks

Date Stock Title
May 14 TVTX Travere tumbles as Teva bags FDA approval for generic of Thiola
May 14 BIIB Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
May 14 PRAX Praxis Precision Medicines to Present at Upcoming Investor Conferences
May 14 BIIB Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study
May 14 BIIB UPDATE 1-Biogen's experimental eye treatment fails to meet study goal
May 14 BIIB Biogen's gene therapy fails to meet phase 2/3 eye disease main goal
May 14 BIIB Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 14 PRAX Praxis Precision secures $91.3M via equity raise
May 14 IONS Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
May 14 PRAX Praxis Precision Medicines Prices Public Offering of Common Stock
May 13 BIIB Biogen, Envisagenics to collaborate on RNA splicing for CNS diseases
May 13 BIIB Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
May 13 BIIB The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
May 13 IONS Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
May 12 BIIB Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
May 12 BIIB Biogen Buys Acute Ischemic Stroke Candidate For One-Time Payment Of $18M
May 12 BIIB Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
May 12 BIIB Biogen exercises option to buy stroke treatment from TMS
May 12 BIIB Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
May 12 IONS Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat

Spinal muscular atrophy (SMA) is a rare neuromuscular disorder characterised by loss of lower motor neurons and progressive muscle wasting, often leading to early death.
The disorder is caused by a genetic defect in the SMN1 gene, which encodes SMN, a protein widely expressed in all eukaryotic cells (that is, cells with nuclei, including human cells) and necessary for survival of motor neurons. Lower levels of the protein results in loss of function of neuronal cells in the anterior horn of the spinal cord and subsequent system-wide atrophy of skeletal muscles.
Spinal muscular atrophy manifests in various degrees of severity, which all have in common progressive muscle wasting and mobility impairment. Proximal muscles, arm and leg muscles that are closer to the torso and respiratory muscles are affected first. Other body systems may be affected as well, particularly in early-onset forms of the disorder. SMA is the most common genetic cause of infant death.
Spinal muscular atrophy is an inherited disorder and is passed on in an autosomal recessive manner. In December 2016, nusinersen (marketed as Spinraza) became the first approved drug to treat SMA while several other compounds remain in clinical trials.

More about Spinal Muscular Atrophy
Browse All Tags